TY - JOUR
T1 - Basic and translational applications of engineered MHC class I proteins
AU - Hansen, Ted H.
AU - Connolly, Janet M.
AU - Gould, Keith G.
AU - Fremont, Daved H.
N1 - Funding Information:
The authors would like to thank the National Institutes of Health, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, and the UK Medical Research Council for financial support, and Dr. Vesselin Mitaksov for the original creation of Figures 1 and 2.
PY - 2010/10
Y1 - 2010/10
N2 - Major histocompatibility complex (MHC) class I molecules can be engineered as single chain trimers (SCTs) that sequentially incorporate all three subunits of the fully assembled proteins, namely peptide, β2 microglobulin, and heavy chain. SCTs have been made with many different MHC-peptide complexes and are used as novel diagnostic and therapeutic reagents, as well as probes for diverse biological questions. Here, we review the recent and diverse applications of SCTs. These applications include new approaches to enumerate disease-related T cells, DNA vaccines, eliciting responses to pre-assembled MHC-peptide complexes, and unique probes of lymphocyte development and activation. Future applications of SCTs will be driven by their further engineering and the ever-expanding identification of disease-related peptides using chemical, genetic and computational approaches.
AB - Major histocompatibility complex (MHC) class I molecules can be engineered as single chain trimers (SCTs) that sequentially incorporate all three subunits of the fully assembled proteins, namely peptide, β2 microglobulin, and heavy chain. SCTs have been made with many different MHC-peptide complexes and are used as novel diagnostic and therapeutic reagents, as well as probes for diverse biological questions. Here, we review the recent and diverse applications of SCTs. These applications include new approaches to enumerate disease-related T cells, DNA vaccines, eliciting responses to pre-assembled MHC-peptide complexes, and unique probes of lymphocyte development and activation. Future applications of SCTs will be driven by their further engineering and the ever-expanding identification of disease-related peptides using chemical, genetic and computational approaches.
UR - http://www.scopus.com/inward/record.url?scp=77957257899&partnerID=8YFLogxK
U2 - 10.1016/j.it.2010.07.003
DO - 10.1016/j.it.2010.07.003
M3 - Review article
C2 - 20832361
AN - SCOPUS:77957257899
SN - 1471-4906
VL - 31
SP - 363
EP - 369
JO - Trends in Immunology
JF - Trends in Immunology
IS - 10
ER -